Gilead Sciences has appointed Dietmar Berger as chief medical officer and a member of its senior leadership team.
Berger, who will assume the role at the beginning of 2025, is a board-certified internist, haematologist and oncologist with more than 25 years of experience in developing and delivering medicines across a wide range of therapeutic areas.
He most recently served as chief medical officer and global head of development at Sanofi, which saw him lead development science, strategy and operations across the company’s therapeutic areas of focus.
Prior to this, Berger was global head of research and development at Atara Biotherapeutics, and held senior development roles at Genentech, Bayer and Amgen.
In his latest position, Berger will be responsible for Gilead’s virology, oncology and inflammation portfolio and will oversee the company’s global development and medical affairs organisations.
Berger said: “I am looking forward to working with the… team at Gilead to continue to advance its promising pipeline and improve health outcomes for communities around the world.”
Also commenting on the appointment, Daniel O’Day, the company’s chairman and chief executive officer, said: “Dietmar’s exceptional leadership in global drug development, his track record in delivering transformational therapies, and the breadth and depth of his experience make him an ideal choice as Gilead’s chief medical officer.”